CLINICAL TRIAL: PHI-59: PHASE I AND PHARMAKOKINETIC STUDY OF VORINOSTAT

临床试验：PHI-59：伏立诺他的 I 期和药代动力学研究

• 批准号: 7982087
• 负责人: Stephen I Shibata
• 金额: $ 3.94万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982087
• 关键词: Advanced Malignant Neoplasm; Adverse effects; Blood; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Investigational Drugs; Pharmaceutical Preparations; Phase; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Vorinostat; liver function; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out the highest possible dose of the investigational drug vorinostat that can be given to subjects with advanced cancer and different degrees of liver function before unmanageable side effects are seen. Other purposes of this research study will be to examine what side effects occur when the drug is given to subjects with different degrees of liver function, how much vorinostat is in the blood at specific times after it is received, and whether or not vorinostat is effective in treating various types of advanced cancer.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是找出在出现无法控制的副作用之前，可以给予晚期癌症和不同程度肝功能受试者的研究药物伏立诺他的最高可能剂量。这项研究的其他目的将是检查当药物给予不同程度肝功能的受试者时会发生什么副作用，在接受后的特定时间血液中有多少vorinostat，以及vorinostat是否有效治疗各种类型的晚期癌症。